跳至主要内容
临床试验/CTRI/2019/04/018669
CTRI/2019/04/018669尚未招募2 期

A Single Blind, Randomized, Parallel Group, Controlled Clinical Study to compare the Efficacy and Safety of a Unani Drug â?? Atrilal (O and T) with Conventional Drug â?? Psoralen (O and T) in the Treatment of Baraá¹£ (Vitiligo) - MVIT

Central Research Institute of Unani Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients of any sex aged18-40 years
  • Non-segmental vitiligo with chronicity of 6 months to 2 years
  • Vitiligo involving more than equal to 2% body surface area (BSA)
  • Patients with less than 5 new lesions in the last month
  • Patients with less than 15 lesions in the last 3 months
  • Patients who have not taken systemic treatment in the last 4 weeks
  • Patients who have not taken topical treatment in the last 2 weeks

排除标准

  • Patients aged less than 18 years or more than 40 years
  • Segmental vitiligo/ lip-tip or universal vitiligo/ vitiligo with leucotrichia
  • Non-Segmental vitiligo with chronicity of less than 6 months or more than 2 years
  • History of photosensitivity/ photo exaggerated dermatoses
  • Pregnant or Lactating Women
  • Significant Pulmonary/ Cardiovascular/ Hepato-renal Dysfunction
  • Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies (cutaneous or internal)
  • Patients not willing to attend treatment schedule regularly
  • Patients not having a suitable facility for sun exposure

研究者

相似试验